Coya Therapeutics Announces $10.0 Million Private Placement
Coya Therapeutics, Inc. (COYA)
Company Research
Source: Business Wire
Majority of investors in offering are existing institutional stockholders of Coya HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq:COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of regulatory T cells (“Tregs”), announced today that it has entered into definitive securities purchase agreements for the purchase and sale of an aggregate of 1,379,314 shares of its common stock in a private placement at a price of $7.25 per share. The offering is expected to close on or about October 23, 2024, subject to the satisfaction of customary closing conditions. The majority of investors in the offering are existing institutional stockholders of the Company.BTIG, LLC is acting as the lead placement agent and Allele Capital Partners, LLC, through its executing broker-dealer, Wilmington Capital Securities, LLC, and Chardan Capital Markets LLC are acting as co-placement agents for the offering
Show less
Read more
Impact Snapshot
Event Time:
COYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COYA alerts
High impacting Coya Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
COYA
News
- Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to StockholdersBusiness Wire
- Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.MarketBeat
- Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.MarketBeat
- Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial ResultsBusiness Wire
- Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
COYA
Sec Filings
- 11/20/24 - Form S-3
- 11/14/24 - Form 4
- 11/13/24 - Form 4
- COYA's page on the SEC website